The New Obesity Definition Explained: BMI Plus Body Fat, Plus 18 Conditions

For the last several decades, body mass index has been the single threshold defining obesity in the US: a BMI of 30 or higher meant you had it, anything below did not. That binary cutoff has well-known limitations — it misclassifies muscular individuals as obese, it misses people with normal BMI but high visceral fat, and it does not distinguish "metabolically healthy" obesity from obesity that is actively driving organ dysfunction.

In January 2025, a Lancet Diabetes & Endocrinology Commission of 58 international experts proposed a different framework. In October 2025, that framework was validated against 301,026 adults in the National Institutes of Health All of Us research program (JAMA Network Open, Aminian et al., DOI 10.1001/jamanetworkopen.2025.37619). Together, these two papers represent the most concrete shift in how obesity is defined and diagnosed in roughly 30 years. Here is what changed.

What the Lancet Commission Actually Proposed

The 2025 Lancet Commission framework keeps BMI as a screening tool, but adds two requirements that change how the diagnosis works:

Requirement 1 — confirm with body fat measurement. A high BMI by itself is not sufficient. The diagnosis requires confirmation either by direct body fat measurement (DXA, BIA) or by an anthropometric measure — waist circumference, waist-to-hip ratio, or waist-to-height ratio. This addresses BMI's biggest weakness: that muscle and bone are heavier than fat, so a strong, dense body can have a high BMI without elevated body fat.

Requirement 2 — distinguish "preclinical" from "clinical" obesity. If you meet the body-fat-confirmed obesity criterion, the framework then asks whether you have organ dysfunction or disease attributable to excess adiposity. The Commission identified 18 obesity-related diseases, including type 2 diabetes, hypertension, dyslipidemia, sleep apnea, fatty liver disease, osteoarthritis, and cardiovascular disease. Presence of at least one means "clinical obesity" (a chronic, systemic disease state). Absence means "preclinical obesity" (excess adiposity without current organ dysfunction).

This second piece is the conceptual shift. Under the old definition, you either had obesity (BMI ≥30) or you did not. Under the new framework, you can have excess adiposity that has not yet caused disease — the preclinical category — which is treated more like a risk factor than a chronic illness.

The Three New Categories

Applied operationally, the framework sorts people into three obesity-status buckets that did not exist before:

• No obesity: Either BMI below the threshold and no elevated anthropometric measure, or BMI above the threshold with all anthropometric measures normal and no body fat confirmation.
• BMI-plus-anthropometric obesity: BMI above the traditional threshold and at least one elevated anthropometric measure (waist circumference, WHR, or waist-to-height ratio).
• Anthropometric-only obesity: BMI below the traditional threshold but at least two elevated anthropometric measures. This is the "normal-BMI obesity" category — people whose total weight does not register as obese, but whose fat distribution carries the same metabolic risk.

Within either of the two obesity categories, the additional question — do you have at least one of the 18 obesity-related diseases — determines whether you are in the preclinical or clinical subcategory.

How Many People Move Into "Obesity" Under the New Definition

The All of Us cohort study (n = 301,026; median age 54; 61% female) applied both definitions to the same population. The results:

• Traditional BMI-only definition: 128,992 of 301,026 (42.9%) classified as having obesity.
• New Lancet framework: 206,361 of 301,026 (68.6%) classified as having obesity.

That is roughly a 60% increase in the obesity prevalence number. Most of the difference is the anthropometric-only category — people with BMI under 30 but with central adiposity that the new framework now captures.

The Risk Numbers — Why the New Framework Was Validated

A definition that classifies more people as obese is only useful if it actually identifies elevated risk. The Aminian et al. analysis tested this by following the cohort prospectively for incident outcomes. Compared to the "no obesity" group, the "clinical obesity" group (obesity plus at least one obesity-related disease) had:

• Adjusted hazard ratio for new-onset diabetes: 6.11
• Adjusted hazard ratio for incident cardiovascular events: 5.88
• Adjusted hazard ratio for all-cause mortality: 2.71

People with anthropometric-only obesity (normal BMI, abnormal fat distribution) also had elevated risk for diabetes, cardiovascular disease, and mortality — meaningfully higher than people without obesity, even though traditional BMI-only screening would have missed them entirely. This is the core argument for the new framework: it captures real risk that BMI alone leaves invisible.

How This Maps to Existing Calculators

None of the individual measurements in the new framework are new. They are familiar tools combined into a different diagnostic logic:

• The BMI Calculator gives the initial screening number. Under the new framework, BMI alone is not the diagnosis — but it is still the entry point.
• The Waist-to-Hip Ratio Calculator and a waist circumference measurement together cover the anthropometric confirmation step.
• The Body Roundness Index Calculator is an alternative central-adiposity measure that some researchers have proposed as a single composite anthropometric.
• The Army Body Fat Calculator gives an estimated body fat percentage that some implementations of the framework use as a direct adiposity confirmation.
• For the clinical-vs-preclinical distinction, the relevant downstream calculators include the PREVENT Equations Calculator for cardiovascular risk and any diabetes-risk assessment a clinician runs.

None of these individually does the full framework diagnosis. A complete classification — BMI threshold, body-fat-or-anthropometric confirmation, and obesity-related disease screening — is a clinical workup, not a single self-administered calculation. But these calculators give you the pieces.

Important Limitations and Caveats

The new framework is not without critics. Several open questions remain:

It is consensus, not yet guideline. The Lancet Commission paper is a position statement endorsed by many medical societies, but it is not yet the standard adopted by the World Health Organization, the CDC, or the major US clinical practice guidelines. Implementation is happening in some preventive cardiology and obesity medicine clinics ahead of any official endorsement.

Sex and race thresholds matter. The framework uses sex- and race-specific anthropometric thresholds. Cutoffs for waist circumference, for example, differ by sex and have additional adjustments for some racial and ethnic groups in some implementations. Calculator outputs depend on which threshold table is used.

Pediatric application is debated. A 2025 commentary in Acta Paediatrica argued that applying the framework to children adds complexity without clear clinical benefit. The framework is primarily aimed at adults.

This is not a diagnosis you can self-administer. A high score on any combination of these calculators does not constitute a clinical obesity diagnosis. The 18-disease screening, the determination of organ dysfunction attributable to adiposity, and any treatment recommendation are all clinical decisions made with a healthcare provider. The calculators on this site provide estimates for informational purposes only and are not a substitute for professional medical advice.

What This Means for Tracking Your Own Numbers

If you use BMI and waist measurements as personal benchmarks, the practical implication of the new framework is straightforward: you were probably already tracking both, and the framework essentially formalizes that you should. A few takeaways:

• BMI alone is not the whole picture — pair it with a waist measurement.
• A normal BMI with elevated waist circumference is its own risk category and worth discussing with a clinician.
• The distinction that matters most clinically is "preclinical" vs "clinical" — i.e., whether elevated adiposity has produced measurable organ effects. Routine labs and screenings (lipids, blood pressure, fasting glucose / A1c, liver enzymes, sleep symptoms) are how that question gets answered.
• A "preclinical obesity" classification is not nothing — it is the category where lifestyle modification has the largest potential preventive impact before disease develops.

The new framework does not change what you can do about elevated adiposity. It changes how the medical system labels it and how risk is communicated. For tracking purposes, the pieces you would measure are the same — just measured together, and interpreted in combination.